eligibility_summary
Inclusion: age 2–70, CD19+ relapsed/refractory ALL, DLBCL (failed anthracycline+anti‑CD20), transformed FL/MZL/CLL/SLL, or CLL after ≥2 lines (Ph+ALL incl. TKIs, late relapse requires failed/ineligible auto‑SCT), ECOG≤2 or Lansky≥50, adequate organ/marrow, therapy washout, contraception. Exclusion: recent auto/allo‑SCT, immunosuppression or GVHD≥2, active CNS disease, other malignancy, HIV/HTLV, uncontrolled infection/illness, pregnancy, MDS, HBV/HCV PCR+, major CNS disorder, autoimmune on immunosupp ≤6 mo, drug hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05705570 (Phase I, single-arm, 3+3). Interventions: 1) MB-CART19.1—autologous, genetically engineered chimeric antigen receptor T-cell therapy (cellular immunotherapy). Mechanism: patient T cells are modified to express a CAR targeting CD19, CAR engagement activates cytotoxic T-cell responses to eliminate CD19+ malignant B cells. 2) Cyclophosphamide—alkylating chemotherapy used for lymphodepletion to enhance CAR-T expansion. 3) Fludarabine—purine analog antimetabolite used for lymphodepletion. Targets: CD19 antigen on B-lineage cells (ALL, NHL, CLL), lymphodepletion reduces host lymphocytes/regulatory cells to facilitate CAR-T activity.